Management of the febrile neutropenic patient: A consensus conference

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 1, 2004, Pages

  Picazo, Juan J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GLYCOPEPTIDE; IMIPENEM; QUINOLONE DERIVATIVE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASPERGILLUS; BACTERIAL ENDOCARDITIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANDIDA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS CATHETER; LEUKEMIA; LYMPHOMA; MORBIDITY; MORTALITY; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN FLORA; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; BACTEREMIA; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, MICROBIAL; FEVER; FUNGEMIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; JAPAN; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES; SEPSIS;

EID: 3242749626     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383041     Document Type: Conference Paper

References (88)

1. Masaoka T. Management of fever of unknown origin in the neutorpenic patient: the Japanese experience. Int J Hematol 1998; 68(Suppl 1): S9-11.
2. Yoshida M, Tsubaki K, Kobayashi T, et al. Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. Int J Hematol 1999; 70:261-7.
3. Hughes WT, Armstrong D, Bodey GP, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25:551-73.
4. Zinner SH. Relevant aspects in the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Int J Hematol 1998; 68(Suppl 1):S31-4.
5. Feld R. Microbial resistance and the Infectious Diseases Society of America (IDSA) guidelines. Int J Hematol 1998; 68(Suppl 1):S27-30.
6. Feld R. Multinational cooperation in trials and guidelines dealing with febrile neutropenia. Int J Antimicrob Agents 2000; 16:185-7.
7. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
8. Masaoka T. Economic issues: toward a cost-effective approach to the management of febrile neutropenia in Japan. Clin Infect Dis 2004; 39(Suppl 1):S68-9 (in this issue).
9. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV. Infections in the neutropenic patient: new views of an old problem. Hematology 2001:113-39.
10. Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clin North Am 2001; 15:457-82.
11. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998; 41(Suppl D):7-11.
12. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29:490-4.
13. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 2002; 15:377-82.
14. Aksu G, Ruhi MZ, Akan H, et al. Aerobic bacterial and fungal infections in peripheral blood stem cell transplants. Bone Marrow Transplant 2001; 27:201-5.
15. Haupt R, Romanengo M, Fears T, Viscoli C, Castagnola E. Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours: a 12-year experience at a single Italian institution. Eur J Cancer 2001; 37:2413-9.
16. Gaytan Martínez J, Mateos García E, Sánchez Cortes E, Gonzalez Llaven J, Casanova Cardiel LJ, Fuentes Allen JL. Microbiological findings in febrile neutropenia. Arch Med Res 2000; 31:388-92.
17. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004; 39(Suppl 1): S25-31 (in this issue).
18. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995; 155:1177-84.
19. Oppenheim BA, Hartley JW, Lee W, Burnie JP. Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. BMJ 1989; 299:294-7.
20. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41(Suppl D):13-24.
21. Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1982; 97:503-8.
22. Flynn PM, Van Hooser B, Gigliotti F. Atypical mycobacterial infections of Hickman catheter exit sites. Pediatr Infect Dis J 1988; 7:510-3.
23. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323-32.
24. Bodey GP. Fungal infection in neutropenic patients: past achievements and future problems. In: Klatersky JA, ed. Febrile neutropenia. Berlin: Springer-Verlag; 1997:89-98.
25. Warnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother 1998; 41(Suppl D):95-105.
26. Haron E, Feld R, Tuffnell P, Patterson B, Hasselback R, Matlow A. Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 1987; 83:17-26.
27. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88-100.
28. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-24.
29. Wingard J. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004; 39(Suppl 1):S38-43 (in this issue).
30. De Pauw BE, Meunier F. Infections in patients with acute leukemia and lymphoma. In: Mandell GL, Bennett JE, Dolin R, eds. General principles in infectious diseases. 5th ed. Vol 2. Philadelphia: Churchill-Livingstone, 2000: 3090-102.
31. Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15:355-67.
32. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-24.
33. Maayan S, Wormser GP, Widerhorn J, Sy ER, Kim YH, Ernst JA. Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome. Am J Med 1987; 83:945-8.
34. Scowden EB, Schaffner W, Stone WJ. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) 1978; 57:527-44.
35. Link K, Orenstein R. Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. South Med J 1999; 92:728-31.
36. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316:927-31.
37. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990; 162:103-8.
38. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72:195-8.
39. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
40. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.
41. Lacey RW. Antibiotic resistance plasmids of Staphylococcus aureus and their clinical importance. Bacteriol Rev 1975; 39:1-32.
42. Barber M, Rozwadowska-Dowzenko M. Infection by penicillin-resistant staphylococci. Lancet 1948; 2:641-4.
43. Murray BE, Mederski Samaroj B. Transferable beta-lactamase: a new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest 1983; 72:1168-71.
44. Wells VD, Wong ES, Murray BE, Coudron PE, Williams DS, Markowitz SM. Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med 1992; 116:285-92.
45. Shlaes DM, Binczewski B, Rice LB. Emerging antimicrobial resistance and the immunocompromised host. Clin Infect Dis 1993; 17(Suppl 2):S527-36.
46. Huycke MM, Spiegel CA, Gilmore MS. Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1991; 35:1626-34.
47. Noskin GA, Till M, Patterson BK, Clarke JT, Warren JR. High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis 1991; 164:1212-5.
48. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996; 40:891-4.
49. Balkundi DR, Murray DL, Patterson MJ, Gera R, Scott Emuakpor A, Kulkarni R. Penicillin-resistant Streptococcus mitis as a cause of septicemia with meningitis in febrile neutropenic children. J Pediatr Hematol Oncol 1997; 19: 82-5.
50. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312-8.
51. Carratalá J, Fernández Sevilla A, Tubau F, Domínguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxadn prophylaxis. Antimicrob Agents Chemother 1996; 40:503-5.
52. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29: 495-502.
53. Rolston KVI, Raad I, Whimbey E, Bodey GP. The changing spectrum of bacterial infections in febrile neutropenic patients. In: Klatersky JA, ed. Febrile neutropenia. Berlin: Springer-Verlag, 1997:53-8.
54. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32(Suppl 2):S104-13.
55. Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49:479-87.
56. Paterson DL, Yu VL. Extended-spectrum beta-lactamases: a call for improved detection and control. Clin Infect Dis 1999; 29:1419-22.
57. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6:460-3.
58. MacKenzie FM, Gould IM. Extended spectrum beta-lactamases. J Infect 1998; 36:255-8.
59. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-7.
60. Dupont B. The pressure of emerging resistance in fungal diseases. In: Klatersky JA, ed. Febrile neutropenia. Berlin: Springer-Verlag, 1997: 99-100.
61. Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004; 39(Suppl 1):S7-10 (in this issue).
62. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:316-22.
63. Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane Allman EF, De Pauw BE. Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996; 32A:1332-9.
64. Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 1998; 41(Suppl D):1-5.
65. Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999; 29: 515-21.
66. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18:1012-9.
67. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-51.
68. Scott S. Identification of cancer patients at high risk of febrile neutropenia. Am J Health Syst Pharm 2002; 59:S16-9.
69. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39(Suppl 1): S32-7 (in this issue).
70. Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96.
71. DesJardin JA, Falagas ME, Ruthazer R, et al. Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med 1999; 131:641-7.
72. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect Dis 1999; 29:508-14.
73. Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology 2001:392-421.
74. Feld R. Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? Support Care Cancer 1998; 6:444-8.
75. Nucci M, Landau M, Silveira F, Spector N, Pulcheri W. Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides. Infect Control Hosp Epidemiol 2001; 22:651-3.
76. Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 2004; 39(Suppl 1):S65-7 (in this issue).
77. Garcia Rodríguez JA, Gobernado M, Gomis M, et al. Guía clínica para la evaluación y el tratamiento del paciente neutropénico con fiebre. Rev Esp Quimioter 2001; 14:75-83.
78. Gillespie T, Masterton RG. Investigation of infection in the neutropenic patient with fever. J Hosp Infect 1998; 38:77-91.
79. Inoue M. Microbiological characteristics in Japan. Antimicrobial resistance and susceptibility patterns. Int J Hematol 1998; 68(Suppl 1): S13-4.
80. Picazo JJ. Microbiology of febrile neutropenia: European data on incidence and resistance. Int J Hematol 1998; 68(Suppl 1):S35-8.
81. De Pauw BE, Donnell JP. Infections in the immunocompromised host: general principles. In: Mandell GL, Bennett JE, Dolin R, eds. General principles in infectious diseases. 5th ed. Vol 2. Philadelphia: Churchill-Livingstone, 2000:3079-90.
82. Rolston KVI. The Infectious Diseases Society of America 2002 Guidelines for the Use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 2004; 39(Suppl 1): S44-8 (in this issue).
83. Yoshida M, Ohno R. Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 2004; 39(Suppl 1):S11-4 (in this issue).
84. Ohyashiki K. Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients. Clin Infect Dis 2004; 39(Suppl 1):S56-8 (in this issue).
85. Tamura K, Imajo K, Akiyama N, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 2004; 39(Suppl 1):S15-24 (in this issue).
86. Urabe A. The clinical features of the neutropenic host: definitions and initial evaluation. Clin Infect Dis 2004; 39(Suppl 1):S53-5 (in this issue).
87. Tamura K. Initial empirical antimicrobial therapy: duration and subsequent modifications. Clin Infect Dis 2004; 39(Suppl 1): S59-64 (in this issue).
88. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 2004; 39(Suppl 1):S49-52 (in this issue).